Received: 22 June 2020
Accepted: 22 September 2020
First Online: 16 October 2020
Ethics approval and consent to participate
: Not applicable.
: All authors have given their consent for publication.
: P.B. has received commercial support as a consultant from Axial Biotherapeutics, CuraSen, Fujifilm-Cellular Dynamics International, IOS Press Partners, LifeSci Capital LLC, Lundbeck A/S Idorsia and Living Cell Technologies LTD. He has received commercial support for grants/research from Lundbeck A/S and Roche. He has ownership interests in Acousort AB and Axial Biotherapeutics and is on the steering committee of the NILO-PD trial. Z.G.O. has received consultancy fees from Lysosomal Therapeutics Inc. (LTI), Sanofi, Idorsia, Prevail Therapeutics, Inceptions Sciences (now Ventus), Ono Therapeutics, Denali, Deerfield, Neuron23, Avrobio and Handl.